Investor Relations

At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill significant therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Most recently, we discovered our Hemopurifier® effectively captures tumor-secreted exosomes, known to kill off the immune cells of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism deployed by all cancers, the Hemopurifier® fills an unmet clinical need that offers the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Previously conducted human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish the Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. Earlier this year, we established "good manufacturing practice" (GMP) manufacturing of the Hemopurifier® in an FDA approved facility and now plan to initialize commercialization in India as we advance clinical strategies in the United States and the European Union.

Recent News